



Esperion Therapeutics, Inc.  
Investor Relations Department  
3891 Ranchero Drive  
Suite 150  
Ann Arbor, MI 48108  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ESPR**

Last Trade:	47.51
Trade Time:	10:12 AM ET Jun 29, 2017
Change:	-0.78 <span style="color: red;">↓</span> (-1.605%)
Day Range	46.86 - 48.92
52-Week Range	9.40 - 49.69
Volume	157,221

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jun 26, 2017*  
[Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe](#)
- Jun 14, 2017*  
[Esperion to Present at the JMP Securities 2017 Life Sciences Conference](#)
- May 31, 2017*  
[Esperion to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 22, 2017*  
[Esperion Provides Update on Common Stock Trading Activity](#)
- May 19, 2017*  
[Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 22, 2017*  
[Annual Report \(10-K\)](#)
- Mar 6, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)